AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12195844
Drug: Nebulised fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised fluticasone propionate (FP) 2 x 0.5 mg/2 ml bd
Trial: 12195844
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 2 mg/kg/day for 4 days followed by 1 mg/kg/day for 3 days (maximum 40 mg then 20 mg)
Trial: 9696374
Drug: Intrathecal mafosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal mafosfamide at a dose of 20 mg once or twice weekly until remission, followed by weekly administrations for consolidation and every 3 to 4 weeks for maintenance
Trial: 8596759
Drug: Oral isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosorbide dinitrate (ISDN) 10 or 20 mg
Trial: 2520814
Drug: Flurbiprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (100 mg, twice daily)
Trial: 2520814
Drug: Naproxen-sodium (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen-sodium (500 mg, twice daily)
Trial: 1155823
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Theophylline and Ephedrine
Trial: 27129908
Drug: Anterior-inferior tibiofibular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior-inferior tibiofibular ligament (AITFL) anatomical repair with augmentation
Trial: 11474002
Drug: virologic nonresponders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: virologic nonresponders (both treatments)
Trial: 9710889
Drug: Anti-tumor necrosis
RxNorm normalized name: G 1 (anti-tumor agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tumor necrosis factor-α monoclonal antibody therapy
Trial: 28063515
Drug: ω‐3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 supplementation (3 g/d of fish oil containing 37% eicosapentaenoic acid and 23% docosahexaenoic acid)
Trial: 28063515
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g/d of sunflower oil containing 65% linoleic acid)
Trial: 23967126
Drug: trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trivalent inactivated influenza vaccine
Trial: 19118379
Drug: Ritonavir 100
RxNorm normalized name: ritonavir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 100 mg once daily
Trial: 19118379
Drug: Ritonavir 100
RxNorm normalized name: ritonavir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 100 mg twice daily
Trial: 9988796
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50 g/day)
Trial: 6168363
Drug: Bleomycin-radiotherapy protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin-radiotherapy protocol (15 mg bleomycin I.V. on alternate days followed by radiation)
Trial: 21904964
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy targeting a blood glucose level between 4.4 and 6.1 mmol/l (n = 125)
Trial: 21904964
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy targeting a blood glucose level less than 11.0 mmol/l (n = 123)
Trial: 14712285
Drug: Horse antithymocyte
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horse antithymocyte globulin 15 mg/kg/day for 5 days
Trial: 14712285
Drug: Rabbit antithymocyte
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit antithymocyte globulin 3.75 mg/kg/day for 5 days
Trial: 9446334
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (chemotherapy and radiotherapy) for advanced rectal cancer (T3N1M0 or T4N2M1) and localized large bowel cancer (G2 and G3 grading)
Trial: 29605500
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment (N=98)
Trial: 26956698
Drug: Sofosbuvir (SOF)
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir (SOF) 400 mg and Velpatasvir (VEL) 100 mg for 12 weeks
Trial: 25694008
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity extracorporeal shockwave therapy (LI-ESWT)
Trial: 25694008
Drug: Placebo/sham therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/sham therapy
Trial: 21672334
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg alendronate once every 2 weeks plus 0.5 μg alfacalcidol daily
Trial: 21672334
Drug: alfacalcidol 0.5
RxNorm normalized name: alfacalcidol 0.5 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfacalcidol 0.5 μg daily alone
Trial: 16394086
Drug: 15% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% glucose (200 mg/m2.min)
Trial: 16394086
Drug: saline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline (50 ml/h)
Trial: 31786652
Drug: Random forest
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random forest model based on pre-treatment ADC image-derived radiomics features
Trial: 18676227
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid (1 g)
Trial: 18676227
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g)
Trial: 16822633
Drug: Azithromycin formulation
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin formulation 1
Trial: 16822633
Drug: Azithromycin formulation
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin formulation 2
Trial: 12838698
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Oratest
Trial: 10393397
Drug: Bolus enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus enalaprilat (0.004 mg/kg)
Trial: 10393397
Drug: Continuous enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous enalaprilat infusion (0.004 mg/kg)
Trial: 26459006
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (conventional medication and physical therapy)
Trial: 18719941
Drug: OXXEL (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXXEL (oxaliplatin 100 mg/m² i.v. on day 1, capecitabine 1,000 mg/m² orally twice daily from day 1 to day 11)
Trial: 18719941
Drug: OXAFAFU (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXAFAFU (oxaliplatin 85 mg/m² i.v. on day 1; 6S‐leucovorin 250 mg/m² i.v. and fluorouracil 850 mg/m² i.v. on day 2)
Trial: 15488877
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg combined with Ramipril 10 mg
Trial: 3422243
Drug: 0.001 molar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.001 molar solution of quinine hydrochloride (placebo rinse)
Trial: 16525097
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg twice a day for 3 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Trial: 16525097
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg twice a day for 5 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Trial: 16525097
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg three times a day for 3 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Trial: 16525097
Drug: Quinine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (30 mg/kg/day divided every 8 hours for 3 days) + Doxycycline (100 mg twice a day for 7 days)
Trial: 14571236
Drug: Palivizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palivizumab (15 mg/kg, intramuscularly, 5 monthly injections)
Trial: 11314410
Drug: Ferric sulfate
RxNorm normalized name: Ferric Sulfate
DrugBank: Ferric sodium citrate (DB13771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric sulfate 15.5% solution (applied for 15 seconds)
Trial: 11314410
Drug: Formocresol solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formocresol solution (five minute procedure of Buckley's formula)
Trial: 8994331
Drug: Parkryl (Mei-Shih),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parkryl (Mei-Shih), 10 mg per day as an adjunct to Madopar
Trial: 8994331
Drug: Jumexal (Labatec),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jumexal (Labatec), 10 mg per day as an adjunct to Madopar
Trial: 6546806
Drug: Pirenzepine, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine, 50 mg twice daily
Trial: 6546806
Drug: Benzilonium bromide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzilonium bromide, 17.5 mg twice daily
Trial: 6546806
Drug: Benzilonium bromide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzilonium bromide, 35 mg twice daily
Trial: 6546806
Drug: Benzilonium bromide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzilonium bromide, 70 mg twice daily
Trial: 31026738
Drug: Brazil nut
RxNorm normalized name: Brazil nut
DrugBank: Brazil nut (DB10510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazil nut group (BN), consumed 1 unit/d of Brazil nuts (∼ 1261 μg/Se) for 2 months.
Trial: 22498739
Drug: CTDa (attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTDa (attenuated oral CTD)
Trial: 18539106
Drug: Denosumab every
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab every 3 months (Q3M; 6, 14, or 30 mg) or every 6 months (Q6M; 14, 60, 100, or 210 mg)
Trial: 18539106
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of denosumab
Trial: 18539106
Drug: Retreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with denosumab (60 mg Q6M)
Trial: 18539106
Drug: Open-label oral
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label oral alendronate weekly
Trial: 10557173
Drug: Intra-articular irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular irrigation injection therapy
Trial: 10557173
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of steroid (Control)
Trial: 8687089
Drug: Cefuroxime prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime prophylaxis (3 g intravenous dose during induction of anaesthesia)
Trial: 2104681
Drug: Cholecystokinin-octapeptide (CCK-OP)
RxNorm normalized name: Cholecystokinin C-terminal octapeptide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholecystokinin-octapeptide (CCK-OP) 50 nanograms per kilogram intravenously over a ten minute period daily
Trial: 2104681
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (placebo) intravenously
Trial: 27058204
Drug: Early rehabilitation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rehabilitation and mobilization in addition to standard treatment
Trial: 24094019
Drug: Elastic ligatures
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastic ligatures aged in the oral environment for 4 weeks
Trial: 24094019
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group of elastic ligatures not subjected to oral degradation
Trial: 18450878
Drug: Observation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation therapy without prescription
Trial: 18450878
Drug: Observation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation therapy with prescription
Trial: 11574363
Drug: rapacuronium 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rapacuronium 1.2 mg/kg
Trial: 11574363
Drug: rapacuronium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rapacuronium 1.0 mg/kg
Trial: 11574363
Drug: rocuronium 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.50 mg/kg
Trial: 11574363
Drug: saline 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline 0.05 mL/kg
Trial: 3354808
Drug: bupivacaine 30
RxNorm normalized name: BUPivacaine 300 MG / meloxicam 9 MG in 10.5 ML Extended Release Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 30 mg plus buprenorphine 0.03 mg (group B, n = 30)
Trial: 3354808
Drug: bupivacaine 30
RxNorm normalized name: BUPivacaine 300 MG / meloxicam 9 MG in 10.5 ML Extended Release Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 30 mg plus buprenorphine 0.045 mg (group C, n = 30)
Trial: 3354808
Drug: bupivacaine 30
RxNorm normalized name: BUPivacaine 300 MG / meloxicam 9 MG in 10.5 ML Extended Release Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 30 mg (group A, n = 30)
Trial: 8445413
Drug: Active specific
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active specific immunotherapy (ASI) with autologous tumor cell-BCG vaccine
Trial: 8445413
Drug: Active specific
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active specific immunotherapy (ASI)
Trial: 354840
Drug: Benzopyranoperidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzopyranoperidine 2 mg
Trial: 354840
Drug: Benzopyranoperidine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzopyranoperidine 4 mg
Trial: 354840
Drug: Codeine sulfate
RxNorm normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine sulfate 120 mg
Trial: 24352875
Drug: CHELT (Cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHELT (Cold air and High Energy Laser Therapy)
Trial: 24352875
Drug: ESWT (Extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESWT (Extracorporeal Shock Waves Therapy)
Trial: 22999730
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training (ET) at 60% of peak oxygen consumption, 2 times weekly for 10 years.
Trial: 19443681
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg once daily with triphasic oral contraceptive (OC)
Trial: 19443681
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg once daily with triphasic oral contraceptive (OC)
Trial: 19443681
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with triphasic oral contraceptive (OC)
Trial: 19443681
Drug: Etoricoxib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (both dosages) with triphasic oral contraceptive (OC)
Trial: 17302652
Drug: Comprehensive vision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive vision and eye examinations with subsequent treatment (new eyeglasses, referrals for occupational therapy, glaucoma management, cataract surgery)
Trial: 17302652
Drug: Comprehensive vision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive vision and eye examinations with subsequent treatment
Trial: 15346658
Drug: Transdermal 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐estradiol 0.05 mg/day
Trial: 11996209
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (0.02 mg ethinylestradiol and 0.1 mg levonorgestrel)
Trial: 11996209
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B (0.03 mg ethinylestradiol and 0.15 mg levonorgestrel)
Trial: 8004298
Drug: Eucapnic Voluntary
RxNorm normalized name: Eucardic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucapnic Voluntary Hyperventilation (EVH) after Methacholine Inhalation Challenge (MIC)
Trial: 8004298
Drug: Methacholine Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine Inhalation Challenge (MIC)
Trial: 8004298
Drug: Methacholine Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine Inhalation Challenge (MIC) after Eucapnic Voluntary Hyperventilation (EVH)
Trial: 2529798
Drug: Loratadine 5
RxNorm normalized name: loratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 5 mg plus pseudoephedrine 120 mg twice a day
Trial: 23863328
Drug: Rabeprazole 0.5‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 0.5‐ or 1.0‐mg/kg granule formulation for 12 weeks (5 or 10 mg for low-weight cohort; 10 or 20 mg for high-weight cohort)
Trial: 23863328
Drug: Rabeprazole 0.5‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 0.5‐ or 1.0‐mg/kg granule formulation for 12 weeks
Trial: 21823172
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (LAI) (150 mg/2 weeks, 405 mg/4 weeks, or 300 mg/2 weeks)
Trial: 21823172
Drug: Oral olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral olanzapine (10, 15, or 20 mg/day)
Trial: 21823172
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (LAI and oral olanzapine)
Trial: 19635216
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine infusion under general anesthesia and 0.1 mg/kg ketamine for 24 hours post-surgery
Trial: 19635216
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine infusion under general anesthesia and 0.05 mg/kg ketamine for 24 hours post-surgery
Trial: 19635216
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine infusion under general anesthesia and 0.01 mg/kg ketamine for 24 hours post-surgery
Trial: 28440024
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of 2 reduced-diameter implants with locator-analog attachments
Trial: 28440024
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading of 4 reduced-diameter implants with locator-analog attachments
Trial: 28440024
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of 2 implants
Trial: 25486131
Drug: Extended-release phentermine
RxNorm normalized name: phentermine / topiramate Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release phentermine and topiramate
Trial: 20068559
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (1 g tablet after breakfast and 1 g tablet after dinner for 24 weeks)
Trial: 16642607
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with routine western medicine (Mannitol, Nifedipine, and Ceftriaxone sodium) for 10 days, starting 9 days after operation.
Trial: 16642607
Drug: Routine western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine western medicine (Mannitol, Nifedipine, and Ceftriaxone sodium).
Trial: 10493335
Drug: PncD vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PncD vaccine (3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F, and 23F conjugated to diphtheria toxoid)
Trial: 10493335
Drug: PncT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PncT vaccine (3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F, and 23F conjugated to tetanus protein)
Trial: 10493335
Drug: PncD and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PncD and PncT vaccines
Trial: 8905945
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg intravenous (group O)
Trial: 7016322
Drug: Melphalan (L-PAM)
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan (L-PAM)
Trial: 7016322
Drug: Melphalan (L-PAM)
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan (L-PAM) + 5-FU (PF)
Trial: 31183750
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training with daily protein supplementation for 10 weeks